Skip to content

Hemab Therapeutics Holdings

US · COAG #3007 by market cap Listed 2026
39.29 -0.57 -1.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/30
  • Rating change
    H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/8/12
  • Rating change
    Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/8/12
  • Rating change
    Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy From Wedbush
    TipRanks · 2026/6/30
  • Rating change
    Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/6/9
  • Rating change
    Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42
    Market Newswire · 2026/5/26
  • Rating change
    Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy From Wedbush
    TipRanks · 2026/8/12
  • Rating change
    Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/5/26
  • Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/11/6
  • Rating change
    H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/6/27
  • J.P. Morgan Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $70
    Market Newswire · 2026/10/16
  • Rating change
    H.C. Wainwright Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $40
    Market Newswire · 2026/6/17
  • Rating change
    Analysts Offer Insights on NA Companies: Cleanspark (CLSK), Hemab Therapeutics Holdings, Inc. (COAG) and Microsoft (MSFT)
    TipRanks · 2026/10/16
  • Earnings Flash (COAG) Hemab Therapeutics Posts Q3 Net Loss $0.58 a Share, Vs. FactSet Est of $0.49 Loss
    MT Newswires · 2026/11/10
  • Rating change
    Rodman & Renshaw Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $56
    Market Newswire · 2026/10/12
  • Evercore Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/11/11
  • Rating change
    Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47
    Market Newswire · 2026/7/14
  • LifeSci Capital Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $65
    Market Newswire · 2026/11/9
  • Rating change
    Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/7/14
  • Rating change
    H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52
    Market Newswire · 2026/7/13
  • Rating change
    Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36
    Market Newswire · 2026/5/26
  • Rating change
    Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39
    Market Newswire · 2026/5/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Hemab Therapeutics Holdings discussion 0 comments

Add a comment